The 36-month beta value for EVH is also noteworthy at 1.57. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 7 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EVH is 110.67M, and at present, short sellers hold a 12.68% of that float. The average trading volume of EVH on October 02, 2024 was 2.44M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EVH) stock’s latest price update
Evolent Health Inc (NYSE: EVH) has seen a decline in its stock price by -3.36 in relation to its previous close of 27.05. However, the company has experienced a -5.63% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-23 that Evolent Health is potentially being taken private at a bid of $3.8 billion, offering a 15% upside to the stock at $32 per share. The company’s revenue growth rates are expected to decelerate, but potential bidding wars may drive up the stock price further. Evolent’s current valuation at 21x forward free cash flow may undervalue the company, potentially leading to higher bids in the future.
EVH’s Market Performance
Evolent Health Inc (EVH) has seen a -5.63% fall in stock performance for the week, with a -15.73% decline in the past month and a 32.42% surge in the past quarter. The volatility ratio for the week is 4.72%, and the volatility levels for the past 30 days are at 3.74% for EVH. The simple moving average for the past 20 days is -12.32% for EVH’s stock, with a -6.33% simple moving average for the past 200 days.
Analysts’ Opinion of EVH
Many brokerage firms have already submitted their reports for EVH stocks, with Truist repeating the rating for EVH by listing it as a “Buy.” The predicted price for EVH in the upcoming period, according to Truist is $33 based on the research report published on August 09, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see EVH reach a price target of $40. The rating they have provided for EVH stocks is “Buy” according to the report published on April 22nd, 2024.
Oppenheimer gave a rating of “Outperform” to EVH, setting the target price at $45 in the report published on March 01st of the current year.
EVH Trading at -5.34% from the 50-Day Moving Average
After a stumble in the market that brought EVH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.31% of loss for the given period.
Volatility was left at 3.74%, however, over the last 30 days, the volatility rate increased by 4.72%, as shares sank -12.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.10% upper at present.
During the last 5 trading sessions, EVH fell by -5.22%, which changed the moving average for the period of 200-days by -12.37% in comparison to the 20-day moving average, which settled at $29.63. In addition, Evolent Health Inc saw -20.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EVH starting from McCarthy Daniel Joseph, who sale 23,693 shares at the price of $30.89 back on Aug 22 ’24. After this action, McCarthy Daniel Joseph now owns 198,809 shares of Evolent Health Inc, valued at $731,790 using the latest closing price.
McCarthy Daniel Joseph, the PRESIDENT of Evolent Health Inc, sale 10,469 shares at $32.38 during a trade that took place back on Aug 23 ’24, which means that McCarthy Daniel Joseph is holding 188,340 shares at $339,008 based on the most recent closing price.
Stock Fundamentals for EVH
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.16 for the gross margin
The net margin for Evolent Health Inc stands at -0.03. The total capital return value is set at -0.01. Equity return is now at value -6.93, with -2.91 for asset returns.
Based on Evolent Health Inc (EVH), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at 0.22. The debt to equity ratio resting at 0.75. The interest coverage ratio of the stock is -0.62.
Currently, EBITDA for the company is 46.38 million with net debt to EBITDA at 5.29. When we switch over and look at the enterprise to sales, we see a ratio of 1.59. The receivables turnover for the company is 6.3for trailing twelve months and the total asset turnover is 0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
In summary, Evolent Health Inc (EVH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
